|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Succinonitrile | CAS 110-61-2 | ||
| NCCH2CH2CN | RTECS WN3850000 | ||
|
Synonyms & Trade Names Butanedinitrile; 1,2-Dicyanoethane; Dinile; Ethylene cyanide; Ethylene dicyanide; Succinic dinitrile |
DOT ID & Guide |
||
|
Exposure Limits |
NIOSH REL: TWA 6 ppm (20 mg/m3) | ||
| OSHA PEL: none | |||
| IDLH N.D. | Conversion 1 ppm = 3.28 mg/m3 | ||
|
Physical Description Colorless, odorless, waxy solid. [Note: Forms cyanide in the body.] |
|||
|
MW: 80.1 |
BP: 509°F |
MLT: 134°F |
Sol: 13% |
|
VP(212°F): 2 mmHg |
IP: ? |
|
Sp.Gr: 0.99 |
|
Fl.P: 270°F |
UEL: ? |
LEL: ? |
|
| Combustible Solid | |||
|
Incompatibilities & Reactivities Oxidizers |
|||
|
Measurement Methods NIOSH Nitriles Crit. Doc. |
|
Personal Protection & Sanitation Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet or contaminated Change: Daily Provide: Eyewash |
First Aid (See procedures) Eye: Irrigate immediately Skin: Water wash immediately Breathing: Respiratory support Swallow: Medical attention immediately |
|
Respirator Recommendations
NIOSH Up to 60 ppm: (APF = 10) Any supplied-air respirator Up to 150 ppm: (APF = 25) Any supplied-air respirator operated in a continuous-flow mode Up to 250 ppm: (APF = 50) Any self-contained breathing apparatus with a full facepiece/(APF = 50) Any supplied-air respirator with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister/Any appropriate escape-type, self-contained breathing apparatus |
|
| Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
| Symptoms Irritation eyes, skin, respiratory system; headache, dizziness, lassitude (weakness, exhaustion), confusion, convulsions; blurred vision; dyspnea (breathing difficulty); abdominal pain, nausea, vomiting | |
|
Target Organs
Eyes, skin, respiratory system, central nervous system, cardiovascular system |
|
| See also: INTRODUCTION |